Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model

Duman, Deniz; Zibandeh, Noushin; Uğurlu, M. Ümit; Çelikel, Çiğdem; Akkoç, Tolga; Banzragch, M.; Genç, Deniz; Özdoğan, Osman; Akkoç, Tunç

doi:10.1007/s11033-019-04736-4

Cited by 22 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs have the potential of liver differentiation, immunomodulatory function, and the ability to produce nutritional factors, making them ideal drugs for the treatment of liver brosis [28]. A number of animal studies have shown that MSCs can safely reverse liver brosis and improve liver function [29][30][31]. In recent years, the immunomodulatory function of MSCs has gradually become the main research target in the treatment of liver brosis.…”

Section: Discussionmentioning

confidence: 99%

Individual Heterogeneity Screened Umbilical Cord Derived Mesenchymal Stem Cells With High Treg Promotion Significantly Recovered the Mouse Liver Fibrosis

Xie

Liu

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundTo compare the heterogeneities of human umbilical cord mesenchymal stem cells (HUCMSCs) derived from different donors and test their therapeutic variations in mouse liver fibrosis model. MethodsThe HUCMSCs derived multiple donors were performed comprehensively analysis and potent assays including expressions of surface markers, viability, growth curve, karyotype analysis, tumorigenicity, differentiation potentials, and immune regulation capability. Then the HUCMSCs with distinct immunomodulatory effects were tested for treating liver fibrosis in mice and then therapeutic effects were observed. ResultsThe HUCMSCs derived multiple donors kept a high consistency in surface marker expressions, viability, growth curve, tumorigenicity in nude mic, but had robust heterogeneities in differentiation potentials and immune regulations. In addition, three HUCMSC lines applied to mice liver fibrosis model had different therapeutic outcomes, in line with individual immune regulation capability. ConclusionThe HUCMSCs derived different donors have individual heterogeneity, which potentially lead to distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make use of the donor-variation of MSCs to screen out guaranteed general indicators of MSCs for specific diseases in further stem cell therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Individual Heterogeneity Screened Umbilical Cord Derived Mesenchymal Stem Cells With High Treg Promotion Significantly Recovered the Mouse Liver Fibrosis

Xie

Liu

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…It was noted that the gene expression levels of IL-1β, IL-6, and INF-γ were reduced. [35][36][37][38] One of the suggested effects of MSCs therapy in LF is their transdifferentiation into hepatic progenitor cells or hepatocytes. This was confirmed by loss of CK90 expression, increased hepatic HGF, MMP-2 mRNA and CK19 mRNA.…”

Section: Msc-based Cell Therapy For Lfmentioning

confidence: 99%

“…28 Fluorescence microscopy have been used to confirm the liver-specific homing of fluorescent MSCs labelling dyes. 35,38,39 The tracking of MSCs was also detected by double staining of anti-human specific nuclear antigen and anti-human albumin. 40 Another tracking methods was the use of superparamagnetic iron oxide (SPIO) nanoparticles-labelled MSCs, followed by their visualization in liver tissue by Prussian blue staining.…”

Section: Msc-based Cell Therapy For Lfmentioning

confidence: 99%

Mesenchymal stem cells versus their extracellular vesicles in treatment of liver fibrosis: Is it possible to compare?

Attia

Khalifa

Rostom

et al. 2021

MRAJ

View full text Add to dashboard Cite

Liver fibrosis (LF) is a worldwide health problem that is associated with a range of complications and high mortality. Due to the scarcity of liver donors, mesenchymal stem cell (MSC) therapy emerged as an alternative therapeutic strategy. However, it is widely accepted that most of the transplanted MSCs exhibit their therapeutic impact mainly via a bystander paracrine (medicinal) capacity. In addition to their secretory proteins, MSCs also produce various types of extracellular vesicles (EVs) that are classiﬁed into three main subtypes: microvesicles, exosomes and apoptotic bodies. Thanks to their peculiar cargo composition (e.g., proteins, lipids, and nucleic acids), EVs serve as an advantageous candidate for cell-free therapy. Recently, MSC-derived EVs (MSC-EVs) have gained the podium due to their regenerative and immunomodulatory effect. In mitigation/treatment of LF, a plethora of recent studies have shown the anti-inflammatory, anti-fibrotic and cytoprotective effects of both MSCs and MSC-EVs in various in vitro and in vivo models of LF. However, despite the limited evidence, we sought in this mini review to sort out the established data and formulate several challenging questions that must be answered to pave the way for further clinical applications. One of the major questions to ask is “Which is the best therapeutic approach, MSCs or MSC-EVs?” We tried to highlight how difficult it might be to compare the two approaches while our understanding of both candidates is still deficient. Among the major obstacles against such comparison is the inaccurate equivalent dose determination, the unknown in vivo behavior, and the undetermined lifespan/fate of each. Currently, the fields of MSCs and MSC-EVs seem to be rich in ideas but lacking in appropriate technologies to test these ideas. Nevertheless, continuous efforts are likely to help resolve some of the challenges listed here.

show abstract

“…Basically, they suppress T cell proliferation and regulate the balance of Th1 (autoimmunity related)/Th2 (allergic disease related). On the other hand, they regulate the immune response with T regulatory cells and control antigen presentation of dendritic cells (Akkoc 2019;Duman et al 2019;Genc et al 2019). All of these modulatory effects are important to control cytokine storm disease.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not

Akkoç

2020

Cell Biology and Translational Medicine, Volume 10

View full text Add to dashboard Cite

On December 31, 2019, novel SARS-CoV2 spread from Wuhan China to more than 200 territories around world and the World Health Organization declared a COVID-19 pandemic on January 30, 2020. At this time there is no particular therapy, drug or vaccine available to deal with COVID-19. Today actual data indicates that about 17% of closed COVID-19 cases died. Health care professionals, ministry of health in countries and the public are trying to read the runes to see when the COVID-19 pandemic will be over. Although mild cases of COVID-19 can be controlled with antiviral, anti-inflammatory and immunomodulatory treatment, severe cases may need intensive care unit support and ventilation. Cytokine storms cause high inflammatory responses and pneumonia in severe cases. Mesenchymal stem cells are immunomodulatory and they have regenerative capacity. In this sense, mesenchymal stem cells may improve the patient's clinical and immunological response to COVID-19.

show abstract

Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model

Cited by 22 publications

References 19 publications

Individual Heterogeneity Screened Umbilical Cord Derived Mesenchymal Stem Cells With High Treg Promotion Significantly Recovered the Mouse Liver Fibrosis

Individual Heterogeneity Screened Umbilical Cord Derived Mesenchymal Stem Cells With High Treg Promotion Significantly Recovered the Mouse Liver Fibrosis

Mesenchymal stem cells versus their extracellular vesicles in treatment of liver fibrosis: Is it possible to compare?

COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not

Contact Info

Product

Resources

About